Control study of autologous stem cell transplantation action glycemic control in patients with type 1 diabetes
Control study of autologous stem cell transplantation action glycemic control in patients with type 1 diabetes
复制标题
DOI：
--
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Hou Ta
中科院分区：
文献类型：
--
作者：
Hou Ta
Objective To compare autologous stem cell transplantation and insulin action glycemic control in patients with type 1 diabetes. Methods A total of 40 patients with newly diagnosed type 1 diabetes patients were divided into transplantation group of 15 patients and 25 cases of insulin groups accorded to treatment, transplantation group treated with autologous hematopoietic stem cell transplantation, insulin group with conventional insulin injection therapy, follow-up of 12 months, 12 months after treatment the adoption of continuous glucose monitoring and evaluation of glycemic control was evaluated. Results Transplantation group after treatment, MBG, LAGE were significantly lower than before treatment(P0.05), after treatment, transplantation group MBG, SDBG, LAGE, MAGE were significantly lower than insulin group(P0.05). After the transplant group therapy significantly reduced HbA1 c compared with before treatment and significantly lower than in the insulin group(P0.05), group 2 patients transplanted insulin were deactivated in 9.3,11.2 months, an average reduction of insulin(53.28±21.29)%, after treatment, the amount of insulin significantly reduced transplant group and significantly lower than the insulin group(P0.05), post-transplant group therapy blood glucose 3.9 mmol/L percentage of time, blood glucose 11.1 mmol/L percentage of time were significantly lower than before treatment, and significantly lower than insulin, glucose(3.9~11.1) mmol/L percentage of time increase in the percentage of time now compared to before treatment, and significantly higher than that in the insulin group(P0.05). All patients with severe adverse reactions occur. Conclusion Compared to conventional insulin injection therapy, autologous hematopoietic stem cell transplantation can effectively control blood sugar with type 1 diabetes,can reduce blood sugar fluctuations, reduce insulin dependence.
